ReviewAIMS microbiology2020
Six decades of lateral flow immunoassay: from determining metabolic markers to diagnosing COVID-19.
Review in AIMS microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 3 syntheses or guidelines pooled it, 167 citations in OpenAlex.
- Effectiveness of testing, contact tracing and isolation interventions among the general population on reducing transmission of SARS-CoV-2: a systematic review.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2023Pooled it
- Influence of seasonal and operator variations on diagnostic accuracy of lateral flow devices during the COVID-19 pandemic: a systematic review and meta-analysis.Clinical medicine (London, England) · 2023Pooled it
- Electronic and electrochemical viral detection for point-of-care use: A systematic review.PloS one · 2021Pooled it
- Surface-Enhanced Raman Spectroscopy for Viral Diagnostics: Principles, Strategies, Clinical Challenges, and Future Directions.Chemical reviews · 2026Review
- Electrochemical Lateral Flow Platforms: Pioneering the Future of Rapid Testing.Molecules (Basel, Switzerland) · 2026Review
- The evolution of next-generation lateral flow assays for bacterial and fungal diagnostics.Mikrochimica acta · 2026Review
- An intelligent signal processing strategy for accurate quantification of composite signals in background fluorescence-quenching lateral flow immunoassay for folic acid.Mikrochimica acta · 2026Article
- A rapid test for protein-DNA interactions.Nucleic acids research · 2026Article
- Rapid commercial CTX-M diagnostics: Performance, limitations and clinical impact.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics.Advances in experimental medicine and biology · 2026Review
- Emerging technologies for in-field plant virus detection: innovations and future directions.The Journal of general virology · 2025Review
- Performance of Colorimetric Lateral Flow Immunoassays for Renal Function Evaluation with Human Serum Cystatin C.Biosensors · 2025Article
- A universal point-of-care immunochromatographic test for the serodiagnosis of hepatitis D.Journal of clinical microbiology · 2025Article
- Biosensors, Artificial Intelligence Biosensors, False Results and Novel Future Perspectives.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- Effects on molecular interactions of hollow gold nanoparticles and antibody for sensitizing P24 antigen determination.RSC advances · 2024Article
- Colorimetric sensing for translational applications: from colorants to mechanisms.Chemical Society reviews · 2024Review
- NFC Smartphone-Based Electrochemical Microfluidic Device Integrated with Nanobody Recognition for C-Reactive Protein.ACS sensors · 2024Article
- Limitations of current techniques in clinical antimicrobial resistance diagnosis: examples and future prospects.npj antimicrobials and resistance · 2024Review
- Unleashing the power of colloidal gold immunochromatographic assays for plant virus diagnostics.MethodsX · 2024Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Technologies based on lateral flow immunoassay (LFIA), known in some countries of the world as immunochromatographic tests, have been successfully used for the last six decades in diagnostics of many diseases and conditions as they allow rapid detection of molecular ligands in biosubstrates. The popularity of these diagnostic platforms is constantly increasing in healthcare facilities, particularly those facing limited budgets and time, as well as in household use for individual health monitoring. The advantages of these low-cost devices over modern laboratory-based analyzers come from their availability, opportunity of rapid detection, and ease of use. The attractiveness of these portable diagnostic tools is associated primarily with their high analytical sensitivity and specificity, as well as with the easy visual readout of results. These qualities explain the growing popularity of LFIA in developing countries, when applied at small hospitals, in emergency situations where screening and monitoring health condition is crucially important, and as well as for self-testing of patients. These tools have passed the test of time, and now LFIA test systems are fully consistent with the world's modern concept of 'point-of-care testing', finding a wide range of applications not only in human medicine, but also in ecology, veterinary medicine, and agriculture. The extensive opportunities provided by LFIA contribute to the continuous development and improvement of this technology and to the creation of new-generation formats. This review will highlight the modern principles of design of the most widely used formats of test-systems for clinical laboratory diagnostics, summarize the main advantages and disadvantages of the method, as well as the current achievements and prospects of the LFIA technology. The latest innovations are aimed at improving the analytical performance of LFIA platforms for the diagnosis of bacterial and viral infections, including COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.